secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0001549595-23-000042
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix signs $60M upfront, $3.4B milestone deal with Seagen for DAC cancer drugs
-------------------------------------------------------------------------------

- Nurix will use DELigase platform to develop protein degraders for conjugation to antibodies by Seagen.
- Upfront cash payment of $60M; eligibility for up to $3.4B in research, development, regulatory and commercial milestones.
- Tiered royalties: mid-single to low double digits on future sales; Nurix retains option for U.S. profit sharing and co-promotion on two products.
- Seagen responsible for conjugation, preclinical/clinical development and commercialization of Degrader-Antibody Conjugates (DACs).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000042/0001549595-23-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000042/nrix-20230906.htm
  HTML page:      https://secwatch.observer/filing/0001549595-23-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer